RAP1A Variant rs7525578 Modifies Glycemic Response to Metformin But Not to Pioglitazone or Gliclazide in the UK...

Area of Science:

• Pharmacogenetics
• Type 2 Diabetes Research
• Molecular Biology

Background:

• Metformin is a first-line treatment for type 2 diabetes (T2D), but individual responses vary.
• Preclinical studies suggest metformin's glucose-lowering effect involves Rap1 signaling in the hypothalamus.
• This pathway is not essential for other diabetes drugs like sulfonylureas or thiazolidinediones.

Purpose of the Study:

• To investigate if a specific intronic RAP1A gene variant (rs7525578) influences how well metformin controls blood sugar in humans.
• To determine if this genetic variant has similar effects with other T2D medications.

Main Methods:

• Analysis of UK Biobank data from men with T2D and HbA1c >6% prescribed metformin (n=7002), pioglitazone (n=587), or gliclazide (n=2654).
• Genotyping using imputed array data.
• Comparison of mean HbA1c levels across different genotypes (CC, CT, TT) for each drug cohort using ANOVA and Tukey post hoc tests.

Main Results:

• The RAP1A variant rs7525578 was significantly associated with HbA1c levels in men taking metformin (P=0.004).
• Men with the CT genotype had a higher mean HbA1c (7.52%) compared to CC homozygotes (7.39%, P=0.002).
• No significant associations were found for pioglitazone or gliclazide users, nor in women.

Conclusions:

• The RAP1A variant rs7525578 is associated with modestly higher HbA1c in men treated with metformin, but not other common diabetes drugs.
• This finding supports the role of Rap1 signaling in metformin's mechanism of action.
• Highlights the potential of pathway-based approaches in T2D pharmacogenetics.